Endocrine pancreas

Endocrine Pancreas Overview

  • The endocrine pancreas primarily consists of the islets of Langerhans, which contain different cell types responsible for hormone secretion:

    • α (Alpha) cells: Produce glucagon.

    • β (Beta) cells: Produce insulin.

    • δ (Delta) cells: Produce somatostatin.

    • F or PP cells: Produce pancreatic polypeptide.

Autonomic Control

  • Secretion of pancreatic hormones is under autonomic control:

    • Sympathetic nervous system (inhibits insulin and stimulates glucagon secretion).

    • Parasympathetic nervous system (stimulates insulin and inhibits glucagon).

Intra-Islet Interactions

  • Intra-islet interactions among cell types are crucial:

    • Insulin from β-cells inhibits glucagon secretion from α-cells, especially after meals, contributing to blood glucose regulation.

    • The spatial arrangement of the cell types aids in effective hormonal communication and modulation.

Insulin Secretion Regulation

  • Cellular Mechanisms of Insulin Secretion:

    • Biphasic insulin release:

    • First Phase: Rapid release of stored insulin (depleted with prolonged glucose stimulation).

    • Second Phase: Sustained release from a reserve pool of insulin.

    • Loss of the first-phase release indicates a decline in β-cell function.

Control Mechanisms for Insulin Secretion

  • Stimulators of Insulin Secretion:

    • High blood glucose levels (hyperglycemia).

    • Amino acids from protein intake.

    • Parasympathetic stimulation (e.g., vagal stimulation during food intake).

    • Ketones (only at high concentrations).

  • Amplifiers:

    • GI hormones (incretins) like GLP-1 and GIP amplify insulin secretion induced by glucose.

  • Inhibitors:

    • Low blood glucose levels.

    • Catecholamines (α2 receptors from sympathetic nerves).

    • Somatostatin.

Posttranslational Processing of Proinsulin

  • Proinsulin is processed to form insulin and C-peptide:

    • C-peptide concentration can help assess β-cell function and differentiate between endogenous and exogenous insulin sources.

    • Cleavage occurs via a regulated pathway, accounting for about 95% of β-cell insulin secretion.

Incretin Effect and Oral Glucose Tolerance Test (OGTT)

  • The incretin effect refers to the greater insulin response seen with oral glucose intake compared to intravenous glucose, as measured by C-peptide levels.

  • OGTT Usage:

    • Tests maximum insulin secretory response.

    • Helps diagnose diabetes mellitus by checking C-peptide levels post-glucose intake.

Effects of Insulin

  • Insulin has anabolic effects in the fed state:

    • Promotes glycogenesis, lipogenesis, and protein synthesis in liver, adipose tissue, and muscle.

    • Inhibits gluconeogenesis, glycogenolysis, lipolysis, ketogenesis, and proteolysis.

  • Major roles in lowering blood glucose concentrations through enhanced glucose uptake in target tissues via GLUT-4 translocation.

Glucagon Secretion Control

  • Glucagon, produced by α-cells, has catabolic effects:

    • Stimulates glycogenolysis and gluconeogenesis when blood glucose is low (brought about by fasting or starvation).

    • Opposes the action of insulin, maintaining glucose levels during fasting.

  • Glucagon secretion is stimulated by:

    • Low blood glucose (hypoglycemia).

    • Amino acids from protein intake.

Conditions for Concurrent Insulin and Glucagon Stimulation

  • During high protein meals, both insulin and glucagon may be stimulated to balance amino acid levels and prevent hypoglycemia.

Hypoglycemia and Causes

  • Possible causes include:

    • Exercise, fasting, exogenous insulin overdose, insulinoma (hypersecretion), and alcohol consumption (which disrupts gluconeogenesis).

  • Whipple's Triad for diagnosis of hypoglycemia includes:

    • Low plasma glucose concentration.

    • Presence of hypoglycemic symptoms.

    • Relief of symptoms upon glucose correction.

Diabetes Mellitus Overview

  • Diabetes has two main types:

    • Type 1 Diabetes Mellitus (T1DM): Characterized by autoimmune destruction of β-cells leading to absolute insulin deficiency and ketoacidosis risk.

    • Type 2 Diabetes Mellitus (T2DM): Associated with insulin resistance and relative insulin deficiency, potentially leading to hyperosmolar hyperglycemic states (HHS) without significant ketosis.

Hemoglobin A1c (HbA1c)

  • A critical marker for the long-term regulation of glucose levels, indicating glycemic control over the past 2-3 months:

    • Normal: <5.7%

    • Pre-diabetes: 5.7% - 6.4%

    • Diabetes: >6.5%

Long-Term Complications of Diabetes

  • Diabetic nephropathy, retinopathy, neuropathy, and atherosclerotic diseases are significant chronic complications resulting from long-standing hyperglycemia and metabolic dysregulation.

  • The formation of Advanced Glycation End-products (AGEs) contributes to cellular damage and the complications associated with diabetes.

Treatment Approaches for Diabetes

  • GLP-1 Receptor Agonists:

    • Exenatide and liraglutide improve glycemic control and provide additional cardiovascular benefits.

    • Act by amplifying insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia.

  • SGLT2 Inhibitors:

    • Promote renal glucose excretion, aid in weight loss, and lower blood pressure without relying on residual β-cell function.

    • Concerns with euglycemic diabetic ketoacidosis as a potential side effect during metabolic stress.